Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma

Name: Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
License: Public Domain

The First Affiliated Hospital with Nanjing Medical University

ClinicalTrials.gov · Datasets · License: Public Domain

thymic carcinoma, thymoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 279511
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.